Coversin

Drug Profile

Coversin

Alternative Names: Coversin; EV 576; PAS-coversin; rEV 576; Tissue targeted Coversin™ - Akari

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Guillain-Barre syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Bullous pemphigoid; Conjunctivitis; Guillain-Barre syndrome; Myasthenia gravis; Sjogren's syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 21 Sep 2017 Akari Therapeutics announces intention to submit NDA to US FDA and MAA to EMA for Paroxysmal nocturnal hemoglobinuria
  • 21 Sep 2017 Akari Therapeutics plans a phase II trial for C5 and LTB4 mediated disorder (including atopic keratoconjunctivitis) in the second half of 2017 (Akari website, July 2017)
  • 21 Sep 2017 Akari Therapeutics plans the phase III CAPSTONE and ASSET trials for Paroxysmal nocturnal haemoglobinuria (Treatment-naive, Treatment-experienced) in USA in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top